期刊文献+

八联重组痘苗病毒的体内外毒性研究

Virulence of recombinant vaccinia virus Tiantan strain with eight exogenous genes combined in vitro and in vivo
原文传递
导出
摘要 为评价本实验室构建的八联重组痘苗病毒rVTT-C-J-8+的体内外毒性,用MTS方法和结晶紫染色方法检测rVTT-C-J-8+的体外细胞杀伤能力;通过鼻腔接毒后小鼠的体重变化检测rVTT-C-J-8+的体内毒性;通过颅内接毒后的小鼠存活率检测rVTT-C-J-8+的神经毒性;通过兔斑形成试验检测rVTTC-J-8+对家兔的致病能力。MTS检测结果表明,rVTT-C-J-8+对5种细胞的生长抑制作用明显低于VTT;结晶紫染色表明,rVTT-C-J-8+只有在BHK21和MDCK细胞具有较明显的细胞间扩散水平;小鼠体重变化和兔斑形成试验结果表明,rVTT-C-J-8+对小鼠体重变化影响较小,同时对兔背部皮肤损伤较小,体内毒力和致病力明显小于VTT;小鼠神经毒性的检测表明,rVTT-C-J-8+对小鼠几乎无神经毒性。结果证明,八联重组痘苗病毒rVTT-C-J-8+具有较低的体内外毒性,副作用较小,为今后多联多价疫苗的生产提供了参考依据。 To assess the virulence of recombinant vaccinia virus contained eight exogenous genes rVTT-C-J-8^+,the cytotoxicity of rVTT-C-J-8^+was assessed by MTS and crystal violet staining assay in vitro.The virulence of rVTT-C-J-8^+was assessed by lesion experiment in rabbit,body weight change experiment and neurotoxicity experiment mice.MTS result showed that the inhibiting effect of rVTT-CJ-8^+on BHK21,HeLa,PK-15,MDCK and Vero cells was significantly lower than that of VTT.Crystal violet staining result showed that rVTT-C-J-8^+had replication capacity only in BHK21 and MDCK cells.Rabbit lesion experiment and mice body weight change experiment results showed that in vivo virulence of rVTT-C-J-8^+was significantly lower than that of VTT.Mice neurotoxicity experiment result showed that rVTT-C-J-8^+has almost no neurotoxicity in mice.In conclusion,rVTT-C-J-8^+has low virulence and less side effects,and provided a reference on the multi-vaccine production.
出处 《中国兽医科学》 CAS CSCD 北大核心 2015年第10期1031-1037,共7页 Chinese Veterinary Science
基金 吉林省重点科技攻关资助项目(20130206041NY) 吉林省产业技术创新战略联盟项目(20140309006YY)
关键词 病毒载体 多联多价疫苗 痘苗病毒 毒性 virus vector multi-vaccine vaccinia virus virulence
  • 相关文献

参考文献18

  • 1VERARDI P H,TITONG A,HAGEN C J.New vaccine and immunotherapeutic uses after smallpox eradication[J].Hum Vaccin Immunother,2012,8(7):961-970.
  • 2ROUSH S W,MURPHY T V.Historical comparisons of morbidity and mortality for vaccine preventable diseases in the United States[J].JAMA,2007,298(18):2155-2163.
  • 3OMER S B,SALMON D A,ORENSTEIN W A,et al.Vaccine refusal,mandatory immunization,and the risks of vaccine-preventable diseases[J].N Engl J Med,2009,360(19):1981-1988.
  • 4CHEN R T,GLASSER J W,RHODES P H,et al.Vaccine Safety Datalink project:a new tool for improving vaccine safety monitoring[J].Pediatrics,1997,99(6):765-773.
  • 5杨卉娟,廖国阳,李卫东.联合疫苗发展概况[J].国际生物制品学杂志,2006,29(2):66-69. 被引量:6
  • 6盛媛,王浩然,胡宁宁,陈智飞,王宏宇,姜爽,周晔,李一权,李霄,金宁一.天坛株痘苗病毒基因缺失弱毒株的构建及鉴定[J].中国兽医学报,2014,34(3):384-389. 被引量:7
  • 7BERTRAM L,JEFFREY O,KAREN V,et al.Vaccinia virus vaccines:past,present and future[J].Antiviral Res,2009,84(1):1-13.
  • 8CONO J,CASEY C G,BELL D M.Smallpox vaccination and adverse reactions.Guidance for clinicians[J].MMWR Recomm Rep,2003,52(RR-4):1-28.
  • 9LANE J M,GOLDSTEIN J.Adverse events occurring after smallpox vaccination[J].Semin Pediatr Infect Dis,2003,14(3):189-195.
  • 10NJERA J L,GMEZ C E,DOMINGO-GIL E,et al.Cellular and biochemical differences between two attenuated poxvirus vaccine candidates(MVA and NYVAC)and role of the C7L gene[J].J Virol,2006,80(12):6033-6047.

二级参考文献40

  • 1吴壮,徐军.Cre/Loxp位点重组酶系统在疾病动物模型建立中的应用[J].国外医学(呼吸系统分册),2004,24(4):254-256. 被引量:4
  • 2程惠蓉,冯洁,陈锐钢.伤寒Vi多糖、白喉、破伤风联合疫苗初探[J].国外医学(预防.诊断.治疗用生物制品分册),2004,27(6):241-245. 被引量:1
  • 3娄元梅,阮力,朱既明.痘苗病毒毒力相关基因的研究进展[J].病毒学报,1996,12(1):88-96. 被引量:2
  • 4Van Damme P,Burgess M.Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults.Vaccine,2004,22:305-308.
  • 5Kosuwon P,Warachit B,Hutagalung Y,et al.Reactogenicity and immunogenicity of reduced antigen content diphtheriatetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.Vaccine,2003,21:4194-4200.
  • 6Pichchero ME,Latiolais T,Bernsterin D,et al.Vaccine antigen interactions after a combination diphtheria-tetanus toxoidacellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-,four-and Mx-month-old infants.Pediatr Infect Dis J,1997,16:863-870.
  • 7Nilsson L,Faldella G,Jacquet J,et al.A fourth dose of DTPaIPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3,5 and 11-12 months of age.Scand J Infect Dis,2005,37:221-229.
  • 8Mills E,Gold R,Thipphawong J,et al.Safety and immunogenicity of a combined five-component pertussis-diphtheriatetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two,four,and six months of age.Vaccine,1998,16:576-585.
  • 9Aristegui J,Dal-Re R,Garrote E,et al.Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria,tetanus,acellular pertussis and hepatitis B (DTPa-HBV)vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine,to infants at 2,4 and 6months of age.Vaccine,1998,16:1976-1981.
  • 10Nolan T,Altmann A,Skeljo M,et al.Antibody persistence,PRP-specific immune memory,and booster responses in infants immunised with a combination DTaP-HBV-IPV/Hib vaccine.Vaccine,2004,23:14 -20.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部